Natera Q1 revenue jumps; raises FY guidance; MRD patents upheld
Natera reported Q1 2026 revenue of $696.6M, raised full-year guidance to $2.74B–$2.82B, and won a court ruling upholding three MRD patents tied to a 30% ongoing royalty and preserved damages vs. Invitae. The update also mentions Signatera stage 1 post-surgery positivity in NSCLC with an indicated ~5x outcome related metric.
Natera, Inc. 82B. The company also said a court upheld three MRD patents in its case against Invitae, with a 30% ongoing royalty and preserved damages, while Signatera post-surgery positivity in stage 1-3 NSCLC was linked to about 5x higher risk.